Trastuzumab/chemotherapy combinations in metastatic breast cancer

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 11, 2002, Pages 38-43

  Ligibel, Jennifer A ^a   Winer, Eric P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; DOCETAXEL; INTERLEUKIN 12; NAVELBINE; PLATINUM; TAXANE DERIVATIVE; TRASTUZUMAB;

BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GENE OVEREXPRESSION; HUMAN; METASTASIS; ONCOGENE NEU; PRIORITY JOURNAL; SURVIVAL TIME;

EID: 0036312233     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70125-5     Document Type: Conference Paper

References (48)

1. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
3. Cancer statistics, 1999
4. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
5. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
6. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer
7. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers - A review
8. HER2 overexpression predicts adjuvant tamoxifen failure for early breast cancer: Complete data at 20 yr of the Naples GUN randomized trial
9. Transformation mediated by the human HER-2 gene independent of epidermal growth factor receptor
10. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
11. Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
12. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
13. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC)
14. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER 2 immunophenotype and gene amplification
15. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
16. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression
17. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
18. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
19. Vinorelbine (Navelbine) in the treatment of breast cancer: The European experience
20. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: A phase II study
21. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma
22. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older
23. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer
24. A phase II, multicentre, UK study of vinorelbine in advanced breast cancer
25. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer
26. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer
27. Multicenter phase II trial of weekly Navelbine plus Herceptin in chemonaive patients with HER2 positive metastatic breast carcinoma
28. A phase III study of docetaxel vs. doxorubicin in patients with metastatic breast cancer who have failed an alkylating containing regimen
29. HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications
30. A phase II trial of weekly docetaxel and Herceptin as first- or second-line treatment in HER2 over-expressing metastatic breast cancer
31. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer
32. Weekly intravenous recombinant humanized anti-HER2 monoclonal antibody (trastuzumab) plus docetaxel in patients with metastatic breast cancer: A pilot study
33. A phase II trial of weekly docetaxel and Herceptin for patients with HER2 overexpressing metastatic breast cancer: Safety, efficacy, and correlation with serum HER2 levels
34. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
35. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma
36. Weekly Taxol and carboplatin regimen in patients with advanced breast cancer: A phase II study
37. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
38. Phase II pilot study of Herceptin combined with Taxotere and carboplatin in metastatic breast cancer patients overexpressing HER2-neu proto-oncogene
39. Taxotere, cisplatin and Herceptin in first-line HER2 positive metastatic breast cancer patients, a phase II pilot study by the Breast Cancer International Research Group
40. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
41. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
42. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
43. Effect of cardiac dysfunction on treatment outcome in the trastuzumab (Herceptin) pivotal trial
44. Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy
45. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer
46. Preliminary cardiac safety and efficacy data from a phase I/II trial of TLC D-99 and trastuzumab in patients with locally advanced or metastatic breast cancer
47. A phase I trial of Herceptin and IL-12 in patients with HER2-overexpressing malignancies
48. A safe, outpatient regimen of Herceptin and IL-2 in HER-2 positive metastatic breast cancer therapy